Literature DB >> 27452949

Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds.

Lisa A Robinson1,2, James K Hammitt3,2,4, Angela Y Chang3,5, Stephen Resch3.   

Abstract

Researchers and policymakers have long been interested in developing simple decision rules to aid in determining whether an intervention is, or is not, cost-effective. In global health, interventions that impose costs per disability-adjusted life year averted less than three and one times gross domestic product per capita are often considered cost-effective and very cost-effective, respectively. This article explores the conceptual foundation and derivation of these thresholds. Its goal is to promote understanding of how these thresholds were derived and their implications, as well as to suggest options for improvement. These thresholds are intended to reflect the monetary value of the benefits to affected individuals, based on their preferences for spending on health vs spending on other goods and services. However, the current values were not rigorously derived, which means that their application may lead to inappropriate conclusions regarding which interventions should be adopted as well as misallocation of resources across health and other investments. Improving the basis for these cost-effectiveness thresholds is of particular importance in low- and middle-income countries, given the limited resources available and the significant needs of their populations.
© The Author 2016. Published by Oxford University Press in association with The London School of Hygiene and Tropical Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Cost-effectiveness analysis; disability-adjusted life years; international health policy; resource allocation; willingness to pay

Mesh:

Year:  2016        PMID: 27452949     DOI: 10.1093/heapol/czw096

Source DB:  PubMed          Journal:  Health Policy Plan        ISSN: 0268-1080            Impact factor:   3.344


  54 in total

Review 1.  Cost-Effectiveness Thresholds: the Past, the Present and the Future.

Authors:  Praveen Thokala; Jessica Ochalek; Ashley A Leech; Thaison Tong
Journal:  Pharmacoeconomics       Date:  2018-05       Impact factor: 4.981

2.  Cost-Utility of Access to Care, a National HIV Linkage, Re-engagement and Retention in Care Program.

Authors:  Catherine Maulsby; Kriti M Jain; Brian W Weir; Blessing Enobun; Melissa Werner; Morey Riordan; David R Holtgrave
Journal:  AIDS Behav       Date:  2018-11

3.  Financial Incentives to Increase Cardiac Rehabilitation Participation Among Low-Socioeconomic Status Patients: A Randomized Clinical Trial.

Authors:  Diann E Gaalema; Rebecca J Elliott; Patrick D Savage; Jason L Rengo; Alex Y Cutler; Irene Pericot-Valverde; Jeffrey S Priest; Donald S Shepard; Stephen T Higgins; Philip A Ades
Journal:  JACC Heart Fail       Date:  2019-05-08       Impact factor: 12.035

4.  Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease.

Authors:  Yawen Jiang; Weiyi Ni
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

5.  Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis.

Authors:  Mark M Janko; Jonah Joffe; Danielle Michael; Lauren Earl; Katherine L Rosettie; Gianna W Sparks; Samuel B Albertson; Kelly Compton; Paola Pedroza Velandia; Lauryn Stafford; Peng Zheng; Aleksandr Aravkin; Hmwe H Kyu; Christopher J L Murray; Marcia R Weaver
Journal:  Vaccine       Date:  2022-05-25       Impact factor: 4.169

6.  The value of point-of-care CD4+ and laboratory viral load in tailoring antiretroviral therapy monitoring strategies to resource limitations.

Authors:  Emily P Hyle; Ilesh V Jani; Katherine L Rosettie; Robin Wood; Benjamin Osher; Stephen Resch; Pamela P Pei; Paolo Maggiore; Kenneth A Freedberg; Trevor Peter; Robert A Parker; Rochelle P Walensky
Journal:  AIDS       Date:  2017-09-24       Impact factor: 4.177

7.  Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China.

Authors:  Lei Tian; Xiaomo Xiong; Qiang Guo; Yixi Chen; Luying Wang; Peng Dong; Aixia Ma
Journal:  Pharmacoeconomics       Date:  2020-09-15       Impact factor: 4.981

8.  Cost-effectiveness of universal HIV testing and treatment: where next?

Authors:  Jean B Nachega; Ethan D Borre; David W Dowdy; Pascalina Chanda-Kapata; Susan Cleary; Elvin H Geng
Journal:  Lancet Glob Health       Date:  2021-03-12       Impact factor: 26.763

9.  Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios.

Authors:  Yawen Jiang; Dan Cai; Daqin Chen; Shan Jiang; Lei Si; Jing Wu
Journal:  Br J Clin Pharmacol       Date:  2021-05-05       Impact factor: 3.716

10.  Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study.

Authors:  Krishna P Reddy; Ankur Gupta-Wright; Katherine L Fielding; Sydney Costantini; Amy Zheng; Elizabeth L Corbett; Liyang Yu; Joep J van Oosterhout; Stephen C Resch; Douglas P Wilson; C Robert Horsburgh; Robin Wood; Melanie Alufandika-Moyo; Jurgens A Peters; Kenneth A Freedberg; Stephen D Lawn; Rochelle P Walensky
Journal:  Lancet Glob Health       Date:  2019-02       Impact factor: 26.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.